Campaign for Modern Medicines (CMM)

CMM

We recently partnered with the Campaign for Modern Medicines (CMM) to urge Congress to get new, safe medicines to market faster by quickly reauthorizing PDUFA (Prescription Drug User Fee Act). We believe this issue is critical for us and our members and we encourage you to get engaged. Go to www.modernmedicines.com for more information on how to show your support, and follow CMM on Facebook or Twitter.

To learn more about PDUFA and why it should matter to you, read this blog post from the Campaign: http://modernmedicines.com/pdufa

ISSUE: Children, Youth and Juvenile Mental Health and Addiction Screening Policy

STATEMENT: The prevalence of mental illness, addiction and serious emotional disorders in children and youth under age 18 is oftentimes not adequately or appropriately diagnosed. At the same time, the efficacy of early treatment for mental illness, addiction and serious emotional disorders is proven and the benefits have been demonstrated.

Mental Health America of Indiana supports and will work to guide and create, consistent with recommendations made by the President’s New Freedom Commission and the Surgeon General, opportunities for systematic, standardized and regular screening of children for mental illness, addiction and serious emotional disorders and youth in any and all appropriate settings including but not limited to public and private schools; child welfare; juvenile courts; and primary care settings. Any screening program must:

  • ensure that only qualified personnel conduct the screening and assessment, and develop the treatment program;
  • ensure that records of the screening, assessment and treatment are kept confidential in accordance with current privacy standards for these types of records; and
  • prohibit discrimination based on the screening, assessment and treatment.
  • require active parental consent
  • not be used as an assessment

MHAI supports all efforts to avoid stigmatization as well as the parent’s right to opt out. Once an illness is identified, treatment must also be made available.

PRIORITY LEVEL III